Application of Microarrays to the Analysis of Gene Expression in Cancer
... “profiling papers” have used this design, which offers the ability to use data from many different individuals but offers no intrinsic control for bias in the patient populations or cell populations used. In both the blocked and randomized profile designs, the sample is typically compared with a com ...
... “profiling papers” have used this design, which offers the ability to use data from many different individuals but offers no intrinsic control for bias in the patient populations or cell populations used. In both the blocked and randomized profile designs, the sample is typically compared with a com ...
genstat - University of Illinois at Urbana
... http://www.bioalgorithms.info/slides.htm and Ying Xu’s lecture ...
... http://www.bioalgorithms.info/slides.htm and Ying Xu’s lecture ...
The insect cytochrome oxidase I gene: evolutionary
... to 228 for COll and 261 for COlll; Clary & Wolstenholme, 1985), and is one of the largest proteincoding genes in the metazoan mitochondrial genome. This enables one to amplify and sequence many more characters (nucleotides), within the same functional complex, than is possible for almost any other m ...
... to 228 for COll and 261 for COlll; Clary & Wolstenholme, 1985), and is one of the largest proteincoding genes in the metazoan mitochondrial genome. This enables one to amplify and sequence many more characters (nucleotides), within the same functional complex, than is possible for almost any other m ...
the Liver - Saudi Medical Journal
... genotype and G/A allele in women with RSA and controls. Previous studies investigated the association of RSA and TNF-α polymorphisms reported contradictory results, Babbage et al (22), showed that the −308A TNF-α polymorphism was not associated with RSA in a Caucasian population of 43 women with RSA ...
... genotype and G/A allele in women with RSA and controls. Previous studies investigated the association of RSA and TNF-α polymorphisms reported contradictory results, Babbage et al (22), showed that the −308A TNF-α polymorphism was not associated with RSA in a Caucasian population of 43 women with RSA ...
Genetic Susceptibility to the Development of Autoimmune Disease
... involvement of many genes [l].As no single gene has been shown to be either necessary for the development of the disease or sufficient to cause it, common disease genes are, therefore, referred to as encoding susceptibility. The involvement of more than one susceptibility gene in the disease process ...
... involvement of many genes [l].As no single gene has been shown to be either necessary for the development of the disease or sufficient to cause it, common disease genes are, therefore, referred to as encoding susceptibility. The involvement of more than one susceptibility gene in the disease process ...
Duchenne Muscular Dystrophy - Parent Project Muscular Dystrophy
... dystrophy. It explains some basic scientific facts and shows the now numerous approaches with which research is trying to find a scientifically justified and thus effective therapy of Duchenne muscular dystrophy. Because scientists in more than one hundred laboratories in many countries of the world ...
... dystrophy. It explains some basic scientific facts and shows the now numerous approaches with which research is trying to find a scientifically justified and thus effective therapy of Duchenne muscular dystrophy. Because scientists in more than one hundred laboratories in many countries of the world ...
NICE guidance on giving intravenous fluids
... of as routine with few consequences, it carries many risks as well as benefits. All IV fluids are drugs requiring a prescription, and can have serious negative effects if not given correctly. As many as one in five patients on IV fluid therapy may experience complications as a result of being given ...
... of as routine with few consequences, it carries many risks as well as benefits. All IV fluids are drugs requiring a prescription, and can have serious negative effects if not given correctly. As many as one in five patients on IV fluid therapy may experience complications as a result of being given ...
Infectious Keratitis: Management Protocols
... combination with an azole or amphotericin B. Treatment should be instituted promptly with topical fortified antifungal drops, initially every hour during the day and every 2 hours over night. Subconjunctival injections may be used in patients with severe keratitis or keratoscleritis. They also can b ...
... combination with an azole or amphotericin B. Treatment should be instituted promptly with topical fortified antifungal drops, initially every hour during the day and every 2 hours over night. Subconjunctival injections may be used in patients with severe keratitis or keratoscleritis. They also can b ...
Case Report Section
... metaphases and rearrangement of the MLL gene. Translocations involving the MLL/11q23 region are the most common genomic aberrations in infant ALL seen in ~80% of cases (Raimondi, 2004). Generally leukemia harboring MLL translocation is clinically aggressive and associated with poor prognosis. The mo ...
... metaphases and rearrangement of the MLL gene. Translocations involving the MLL/11q23 region are the most common genomic aberrations in infant ALL seen in ~80% of cases (Raimondi, 2004). Generally leukemia harboring MLL translocation is clinically aggressive and associated with poor prognosis. The mo ...
A small change can make a big difference
... A VNS Therapy is not brain surgery. Implanting the device involves a simple surgical procedure that requires only two small incisions (in the neck and in the left chest area). It is a short procedure usually done under general anaesthesia and entails only a short stay in the hospital. Q Does the i ...
... A VNS Therapy is not brain surgery. Implanting the device involves a simple surgical procedure that requires only two small incisions (in the neck and in the left chest area). It is a short procedure usually done under general anaesthesia and entails only a short stay in the hospital. Q Does the i ...
Estimating lethal allele frequencies in complex pedigrees via gene
... The GC method was proposed by ALLAIRE et al. (1982). This approach calculates the expected lethal allele frequency from known individual genotypes (carriers) among a set of relevant ancestors. Here we used a Fortran program written by LIDAUER and ESSL (1994) based on a concept developed by ALLAIRE e ...
... The GC method was proposed by ALLAIRE et al. (1982). This approach calculates the expected lethal allele frequency from known individual genotypes (carriers) among a set of relevant ancestors. Here we used a Fortran program written by LIDAUER and ESSL (1994) based on a concept developed by ALLAIRE e ...
Duplication of an approximately 1.5 Mb DNA segment
... the distal end of chromosome 5q was used in this assay to detect allelic changes at critical chromosome 5q22qter segment. Twenty three out of 50 patients with sporadic nonpapillary RCCs were heterozygous for the locus D5S22 and 11 tumours from these patients showed a duplication of one allele at chr ...
... the distal end of chromosome 5q was used in this assay to detect allelic changes at critical chromosome 5q22qter segment. Twenty three out of 50 patients with sporadic nonpapillary RCCs were heterozygous for the locus D5S22 and 11 tumours from these patients showed a duplication of one allele at chr ...
Chapter 4 Extensions of Mendel
... Variable expressivity and incomplete penetrance may result from developmental noise as well as from variations in genetic background and environment. Developmental noise refers to random variation in the growth and development of cells and tissues during the generation of the organism. What is a goo ...
... Variable expressivity and incomplete penetrance may result from developmental noise as well as from variations in genetic background and environment. Developmental noise refers to random variation in the growth and development of cells and tissues during the generation of the organism. What is a goo ...
Functional analyses of genetic pathways controlling
... analyses have been used to suggest that transitions between a unipartite and bipartite perianth have occurred multiple times within the eudicots (Albert et al., 1998; Soltis et al., 2005; Zanis et al., 2003). These analyses, though, are equivocal in determining the direction of such evolutionary tra ...
... analyses have been used to suggest that transitions between a unipartite and bipartite perianth have occurred multiple times within the eudicots (Albert et al., 1998; Soltis et al., 2005; Zanis et al., 2003). These analyses, though, are equivocal in determining the direction of such evolutionary tra ...
Supplemental Table 1 and Figure Legends
... ** evaluated by immunohistochemistry (ER, cut off= 10% positive cells; PR, cut off_10% positive cells) according to Hammond M.E. et al . J Clin Oncol 2010; 28:2784-95. ...
... ** evaluated by immunohistochemistry (ER, cut off= 10% positive cells; PR, cut off_10% positive cells) according to Hammond M.E. et al . J Clin Oncol 2010; 28:2784-95. ...
Xylitol production using recombinant Saccharomyces
... selection marker neo r and an auxotrophic marker URA3. The multiple XYL1 genes were stably maintained on the chromosome even after 21 and 10 days in the non-selective sequential batch and chemostat cultures, respectively, whereas S. cere6isiae 2805:pVTXR, which harbors the episomal plasmid pVTXR hav ...
... selection marker neo r and an auxotrophic marker URA3. The multiple XYL1 genes were stably maintained on the chromosome even after 21 and 10 days in the non-selective sequential batch and chemostat cultures, respectively, whereas S. cere6isiae 2805:pVTXR, which harbors the episomal plasmid pVTXR hav ...
uncorrected page proofs
... During meiosis, the pair of number-11 chromosomes disjoin, carrying the alleles to different gametes. Tracey’s eggs have either the A allele or the a allele. This also applies to the sperm cells produced by John. This separation of the alleles of one gene into different gametes that occurs during me ...
... During meiosis, the pair of number-11 chromosomes disjoin, carrying the alleles to different gametes. Tracey’s eggs have either the A allele or the a allele. This also applies to the sperm cells produced by John. This separation of the alleles of one gene into different gametes that occurs during me ...
Precancerous Skin Lesions - Actas Dermo
... microscopes offer the possibility of rapid examination of multiple lesions in a few minutes. ...
... microscopes offer the possibility of rapid examination of multiple lesions in a few minutes. ...
Immunosuppressive therapy and sarcoidosis
... Sakai R. et al. The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. Mod Rhematol ...
... Sakai R. et al. The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. Mod Rhematol ...
High mutation rates in human and ape pseudoautosomal genes
... (Lien et al., 2000). The long (Xq/Yq) arms contain a much smaller q-PAR, which is about 0.4 Mb long (Ciccodicola et al., 2000). Though the p-PAR was demonstrated to be the same in humans, great apes and old world monkeys (Ellis et al., 1990), the q-PAR exists only in humans (this region is X-linked ...
... (Lien et al., 2000). The long (Xq/Yq) arms contain a much smaller q-PAR, which is about 0.4 Mb long (Ciccodicola et al., 2000). Though the p-PAR was demonstrated to be the same in humans, great apes and old world monkeys (Ellis et al., 1990), the q-PAR exists only in humans (this region is X-linked ...
What is Biotechnology
... • Diagnostics for detecting genetic diseases • Gene therapy (e.g. ADA, CF) • Vaccine development (recombinant vaccines) ...
... • Diagnostics for detecting genetic diseases • Gene therapy (e.g. ADA, CF) • Vaccine development (recombinant vaccines) ...
Idiopathic Pulmonary Fibrosis in a Child
... order to reverse the deleterious processes so as to restore normal pulmonary epithelium and oxygenation. Several medications have been proposed which include glucocorticosteroids as well as chloroquine, cyclophosphamide, azathioprine, or colchicine.(4,12) High-dose pulse corticosteroid therapy may b ...
... order to reverse the deleterious processes so as to restore normal pulmonary epithelium and oxygenation. Several medications have been proposed which include glucocorticosteroids as well as chloroquine, cyclophosphamide, azathioprine, or colchicine.(4,12) High-dose pulse corticosteroid therapy may b ...
Determining whether Huntaway dogs treated with AAV2/8 viral
... effects. For example, a number of studies of AAV vectors used to treat models of haemophilia A and B in dogs have reported that treated dogs showed significant improvement in haemophilia symptoms and the presence of episomal vector DNA for up to 16 months, five and a half years, and eight years (Her ...
... effects. For example, a number of studies of AAV vectors used to treat models of haemophilia A and B in dogs have reported that treated dogs showed significant improvement in haemophilia symptoms and the presence of episomal vector DNA for up to 16 months, five and a half years, and eight years (Her ...
Gene therapy
Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy could be a way to fix a genetic problem at its source. The polymers are either expressed as proteins, interfere with protein expression, or possibly correct genetic mutations.The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a ""vector"", which carries the molecule inside cells.Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. By the late 1980s the technology had already been extensively used on animals, and the first genetic modification of a living human occurred on a trial basis in May 1989 , and the first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred on September 14, 1990, when Ashanti DeSilva was treated for ADA-SCID. By January 2014, some 2,000 clinical trials had been conducted or approved.Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique. These include treatment of retinal disease Leber's congenital amaurosis, X-linked SCID, ADA-SCID, adrenoleukodystrophy, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), multiple myeloma, haemophilia and Parkinson's disease. Between 2013 and April 2014, US companies invested over $600 million in the field.The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers. In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.